
|Videos|March 29, 2017
Novel Agents for Neoadjuvant TNBC Treatment
Author(s)Anees B. Chagpar, MD
Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
4
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
5































